- Home
- NBIX vs MEDP Comparison
NBIX vs MEDP Comparison
Compare NBIX & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- MEDP
- Stock Information
- Founded
- NBIX 1992
- MEDP 1992
- Country
- NBIX United States
- MEDP United States
- Employees
- NBIX N/A
- MEDP N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- Sector
- NBIX Health Care
- MEDP Health Care
- Exchange
- NBIX Nasdaq
- MEDP Nasdaq
- Market Cap
- NBIX 14.4B
- MEDP 13.4B
- IPO Year
- NBIX 1996
- MEDP 2016
- Fundamental
- Price
- NBIX $150.87
- MEDP $585.82
- Analyst Decision
- NBIX Strong Buy
- MEDP Hold
- Analyst Count
- NBIX 18
- MEDP 11
- Target Price
- NBIX $172.06
- MEDP $451.70
- AVG Volume (30 Days)
- NBIX 1.0M
- MEDP 347.3K
- Earning Date
- NBIX 10-28-2025
- MEDP 10-22-2025
- Dividend Yield
- NBIX N/A
- MEDP N/A
- EPS Growth
- NBIX 12.44
- MEDP 25.36
- EPS
- NBIX 4.19
- MEDP 14.32
- Revenue
- NBIX $2,682,700,000.00
- MEDP $2,358,373,000.00
- Revenue This Year
- NBIX $23.68
- MEDP $21.48
- Revenue Next Year
- NBIX $18.02
- MEDP $11.90
- P/E Ratio
- NBIX $35.78
- MEDP $41.35
- Revenue Growth
- NBIX 19.61
- MEDP 13.88
- 52 Week Low
- NBIX $84.23
- MEDP $250.05
- 52 Week High
- NBIX $157.67
- MEDP $625.00
- Technical
- Relative Strength Index (RSI)
- NBIX 59.16
- MEDP 62.02
- Support Level
- NBIX $133.62
- MEDP $572.12
- Resistance Level
- NBIX $157.67
- MEDP $602.54
- Average True Range (ATR)
- NBIX 4.58
- MEDP 20.93
- MACD
- NBIX 0.98
- MEDP -0.69
- Stochastic Oscillator
- NBIX 67.98
- MEDP 59.40
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.